John Martin - Gilead

John Martin - Gilead
Total Compensation: $15.6 million

Details: Martin picked up a raise over 2010, when he pulled down $14.2 million. His base salary went up by less than $100,000, but the value of his option awards grew by more than $1 million, topping his then-high gross of $14.7 in 2009.

While Gilead ($GILD) has long found success with its HIV treatments, the company is trying to diversify, starting with last year's $11 billion buyout of Pharmasset, netting that company's promising hepatitis C drug PSI-7977, currently moving through clinical trials. Gilead reported 20% growth in sales of its flagship HIV drugs, and it boosted its R&D spending by 80% in Q1, dropping $458 million on its pipeline, Reuters reported. There has been some backlash, though, as the company came under fire last year for its pricing of HIV meds, some of which can cost as much as $20,000 per year, making them near cost-prohibitive for some providers.

John Martin - Gilead
Read more on

Suggested Articles

Three facts about how distributors are managing in-demand inventory.

Novartis’ latest campaign with a celebrity dance partner asks people to bust a move to raise awareness around sickle cell anemia and therapy Adakveo.

Purdue has reached an $8 billion settlement with the U.S. government to settle criminal and civil charges for its role in the U.S. opioid crisis.